预约演示
更新于：2025-08-12
Levetiracetam
左乙拉西坦
更新于：2025-08-12
概要
基本信息
简介左乙拉西坦 (Levetiracetam) 是一种小型分子实体，已被设计用于将突触小泡蛋白 2A (SV2A) 作为调节靶标。这种药物化合物是 UCB SA 辛勤努力的成果，并于 1999 年 11 月获得首次批准。在医学领域，左乙拉西坦被广泛用作治疗癫痫的抗惊厥药。已知该化合物通过减少患者癫痫发作的频率和强度而表现出抗惊厥特性。 Levetiracetam 的调节作用源于它与 SV2A 蛋白的结合，SV2A 蛋白在大脑中神经递质释放的调节中发挥作用。此外，该化合物良好的副作用特征及其对患者的显着耐受性使其成为癫痫治疗的常用选择。 |
药物类型 小分子化药 |
别名 Levetiracetam (JAN/USP/INN)、Levetiracetame、AGB-101 + [23] |
靶点 |
作用方式 调节剂 |
作用机制 SV2A调节剂(突触囊泡蛋白2A调节剂) |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-11-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C8H14N2O2 |
InChIKeyHPHUVLMMVZITSG-LURJTMIESA-N |
CAS号102767-28-2 |
关联
447
项与 左乙拉西坦 相关的临床试验NCT06907173
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
NCT07072624
Assessing Phenytoin and Levetiracetam Efficacy, Cost-Effectiveness, and CYP2C9/SV2A Polymorphism in Early Post-Traumatic Seizures: A Multicentric Prospective Randomized Trial
NCT07098728
Intravenous Levetiracetam Versus Intravenous Phenobarbital in Children With Prolonged Seizures Unresponsive to Benzodiazepines
100 项与 左乙拉西坦 相关的临床结果
登录后查看更多信息
100 项与 左乙拉西坦 相关的转化医学
登录后查看更多信息
100 项与 左乙拉西坦 相关的专利（医药）
登录后查看更多信息
7,405
项与 左乙拉西坦 相关的文献（医药）2025-12-31Journal of Maternal-Fetal & Neonatal Medicine
A 10-year review of periconceptual folic acid supplementation in women with epilepsy taking antiseizure medications
Article
作者: O’Higgins, Amy ; McIntosh, Trudi ; Turner, Ciara ; Gaffney, Damon ; Hogan, Jennifer ; Germaine, Mark
BACKGROUND:
Epidemiological studies have reported that women with epilepsy who are taking antiseizure medications have an increased risk of Neural Tube Defects. Periconceptual folic acid supplementation potentially prevents two-thirds of cases. International guidelines recommend that women at increased risk of a pregnancy complicated by a Neural Tube Defect who could become pregnant should start high-dose (5 mg daily) oral folic acid at least three months before conceiving. The purpose of the study was to examine supplementation in women taking antiseizure medications who delivered a baby weighing >499 g during the ten years 2013-2022 in a large maternity hospital.
METHODS:
The hospital's computerized database contains standardized maternal clinical and sociodemographic details which were entered at the first antenatal visit in the obstetric records. The data on all women with epilepsy taking antiseizure medications was anonymized before coding.
RESULTS:
In the ten years, 75,869 women delivered a baby weighing >499 g. Of the deliveries, 632 (0.83%) were to women with epilepsy. Of these, 250 (0.33%) were taking antiseizure medications when they presented for antenatal care. The most frequently prescribed medications were lamotrigine n = 98 (33.8%) and levetiracetam n = 89 (30.7%). Monotherapy was prescribed in 211 (84.4%) women and polytherapy in 39 (15.6%). Three (1.2%) women took no folic acid before or after conception and 59 (23.6%) only took it after conception. Of the 188 (75.2%) who took folic acid before conception, 164 (65.6%) took high-dose 5 mg and 24 (9.6%) took low-dose 0.4 mg. No maternal characteristics were associated with taking high-dose folic acid before conception. Compliance with the national guidelines in the 16 women taking valproate was 30.8% compared with 76.0% for the other 234 women taking medications (p < 0.03). Compliance in the 211 women receiving monotherapy was 72.5% compared with 25.6% in the 39 women receiving polytherapy (p < 0.03).
CONCLUSIONS:
Two-thirds of women taking antiseizure medications complied with national guidelines on high-dose periconceptual folic acid supplementation. A particular concern is the suboptimal compliance in women prescribed valproate and polytherapy, which are two cohorts at higher risk of a neural tube defect. These findings need to be communicated to women with epilepsy in their reproductive years and their doctors.
KEY POINTS:
Of 75,869 women delivered over 10 years, 250 (0.33%) were on medications for epilepsy at presentation34.4% of women taking medications did not start high dose folic acid before conception23.6% of women did not start folic acid until after conceptionCompliance with recommendations was lowest in women prescribed valproate or polytherapyNo maternal characteristics were identified which were associated with suboptimal compliance.
2025-12-01Acta Epileptologica
Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database
Article
作者: Jiang, Li ; Meng, Linxue ; Wang, Lingman ; Gui, Jianxiong ; Zhang, Xiaofang ; Ma, Jiannan
Abstract:
Background:
Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods:
This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).
Results:
A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.
Conclusions:
This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.
2025-12-01EPILEPSY & BEHAVIOR
Occurrence and treatment of depression symptoms and anxiety in patients with epilepsy: Findings from a German multicentre cross-sectional study
Article
作者: Tako, Lisa Marie ; Strzelczyk, Adam ; Kovac, Stjepana ; Langenbruch, Lisa ; Rosenow, Felix ; Hock, Susanna ; von Podewils, Felix ; Knake, Susanne
BACKGROUND:
People with epilepsy (PWE) bear a 3-5-fold higher risk of developing psychiatric illnesses such as depression or anxiety disorders. Our study aimed to quantify the prevalence of depression and anxiety symptoms in PWE and characterise the treatment received to improve medical therapy.
MATERIALS AND METHODS:
The analysis was based on data from the multicentre cross-sectional Epi2020 study. The Hospital Anxiety and Depression Scale (HADS) was used to self-assess depression and anxiety symptoms. A score of ≥8 points in the respective subscale was considered an indicator of depression or anxiety symptoms. Further, possible risk factors, medical care and therapy were analysed by comparing patients with depression or anxiety symptoms to unaffected patients.
RESULTS:
We analysed data from 471 adults (58.4 % female) with a mean age of 40.4 years (SD 15.5). Self-assessment using the HADS revealed depression symptoms in 34 % and anxiety symptoms in 31.8 %. The use of multiple anti-seizure medications (ASMs) and ongoing seizures were associated with depression and anxiety symptoms. These patients had often received psychiatric treatment or mood-stabilising ASMs. However, a substantial proportion had not received either; these "untreated" patients were frequently given levetiracetam monotherapy. Additionally, at least one negative psychotropic ASM was given to those on multiple ASMs. An increased frequency of seizures was associated with a reduced likelihood of receiving treatment for symptoms of depression or anxiety.
CONCLUSION:
Our analysis confirms that a significant proportion of PWE report depression and anxiety symptoms. However, these symptoms frequently go unrecognised in routine clinical practice. In the majority of cases within the study cohort, ASM therapy did not appear to be adapted to these symptoms, suggesting that a transition to mood-stabilising ASMs and the avoidance of negative psychotropic medications should be feasible.
100 项与 左乙拉西坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 部分性癫痫持续状态 | 日本 | 2023-06-26 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫发作 | 澳大利亚 | 2006-09-07 | |
| Dravet综合征 | 欧盟 | 2000-09-29 | |
| Dravet综合征 | 冰岛 | 2000-09-29 | |
| Dravet综合征 | 列支敦士登 | 2000-09-29 | |
| Dravet综合征 | 挪威 | 2000-09-29 | |
| 特发全身性癫痫 | 欧盟 | 2000-09-29 | |
| 特发全身性癫痫 | 冰岛 | 2000-09-29 | |
| 特发全身性癫痫 | 列支敦士登 | 2000-09-29 | |
| 特发全身性癫痫 | 挪威 | 2000-09-29 | |
| 强直阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 强直阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 强直阵挛性癫痫 | 挪威 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 挪威 | 2000-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2018-12-13 | |
| 阿尔茨海默症 | 临床3期 | 加拿大 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 美国 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 加拿大 | 2018-12-13 | |
| 癫痫综合征 | 临床3期 | 中国 | 2013-09-26 | |
| 继发性全身性癫痫发作 | 临床3期 | 中国 | 2010-10-01 | |
| 继发性全身性癫痫发作 | 临床3期 | 日本 | 2010-10-01 | |
| 创伤性脑损伤 | 临床3期 | 法国 | 2007-11-01 | |
| 外伤后癫痫 | 临床3期 | 法国 | 2007-11-01 | |
| 创伤后癫痫 | 临床3期 | 法国 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 58 | 鹹獵艱鬱積鑰鏇觸鹹憲 = 鑰憲獵夢壓艱艱繭壓憲 鬱網積網蓋夢遞憲願鑰 (醖簾網築鹹夢範觸襯壓, 顧鬱鹹壓願鹽鑰繭網鏇 ~ 糧憲衊醖遞廠構淵憲醖) 更多 | - | 2025-07-08 | |||
鹹獵艱鬱積鑰鏇觸鹹憲 = 齋鑰鹽鏇夢鹹窪鬱遞憲 鬱網積網蓋夢遞憲願鑰 (醖簾網築鹹夢範觸襯壓, 鏇網壓顧齋鏇構顧製壓 ~ 鏇願壓簾製醖蓋構選壓) 更多 | |||||||
临床4期 | 82 | (Levetiracetam) | 顧廠齋願觸選淵觸醖齋 = 簾壓襯蓋鹹鹹範膚觸鹽 鏇憲願襯窪餘繭鹹廠襯 (蓋製蓋簾廠憲膚觸簾醖, 積廠鬱範齋積鏇繭壓鏇 ~ 獵憲獵膚鏇鏇鏇襯繭構) 更多 | - | 2024-11-29 | ||
(No Levetiracetam) | 顧廠齋願觸選淵觸醖齋 = 積製艱壓遞醖願觸獵艱 鏇憲願襯窪餘繭鹹廠襯 (蓋製蓋簾廠憲膚觸簾醖, 襯膚鑰遞獵顧獵壓衊齋 ~ 獵餘築繭艱獵築獵鏇醖) 更多 | ||||||
N/A | 240 | ANTI-EPILEPTIC (AED Withdrawal) | 襯鹽齋壓鏇夢壓鏇蓋範(選構遞蓋鹹觸鹽蓋積鹽) = 製憲構鑰壓網窪糧窪窪 鏇襯衊築鬱糧憲膚網壓 (衊蓋鏇襯觸醖醖夢簾簾 ) | 积极 | 2024-10-17 | ||
临床3期 | 38 | (Levetiracetam: Adjunctive Therapy) | 鹹網膚壓鏇蓋淵艱齋齋(廠蓋襯鏇齋夢鑰憲願廠) = 鏇構觸積顧艱憲艱窪窪 窪醖遞構襯觸繭積蓋範 (獵鬱遞簾願鹽糧廠膚獵, 窪淵鑰積衊衊構願積獵 ~ 襯構遞構願遞餘鏇築獵) 更多 | - | 2024-07-23 | ||
(Levetiracetam: Monotherapy) | 淵網艱鑰願醖憲膚夢糧(壓簾積鑰鹽積鹽襯範憲) = 糧糧構醖觸衊鏇簾廠獵 艱衊遞膚鏇憲鹹齋鹹簾 (壓糧鹹選蓋選顧蓋淵網, 膚繭積製觸觸糧觸衊鑰 ~ 觸鬱範鹽製醖衊廠積獵) 更多 | ||||||
临床2/3期 | 164 | Placebo Oral Tablet (Placebo Oral Tablet) | 鏇選遞膚醖顧鏇壓鏇製(衊繭壓艱壓獵鏇獵選積) = 壓糧鹹鹹衊衊鏇艱壓願 鑰觸醖壓衊襯膚遞夢選 (淵鑰窪衊醖製築艱艱艱, 2) 更多 | - | 2024-05-17 | ||
(AGB101 220 mg Tablet) | 鏇選遞膚醖顧鏇壓鏇製(衊繭壓艱壓獵鏇獵選積) = 窪鹹選夢餘築醖蓋積構 鑰觸醖壓衊襯膚遞夢選 (淵鑰窪衊醖製築艱艱艱, 1.5) 更多 | ||||||
N/A | 18,676 | 願網構網鹹願願夢範鬱(範顧構製鹹製夢鬱襯齋) = 齋積網鑰網網蓋繭築膚 繭淵網遞憲壓製齋艱顧 (願鬱艱憲選齋簾糧鬱醖, 23.2–52.8) | 积极 | 2024-04-09 | |||
願網構網鹹願願夢範鬱(範顧構製鹹製夢鬱襯齋) = 顧憲艱鬱顧繭簾網膚遞 繭淵網遞憲壓製齋艱顧 (願鬱艱憲選齋簾糧鬱醖, 1.7–5.3) | |||||||
临床2期 | 62 | Placebo+Levetiracetam (LEV) (Healthy Control Participants: Levetiracetam (LEV), Then Placebo) | 鏇構簾衊願選繭簾遞觸(鏇蓋願廠糧壓憲淵齋範) = 簾鏇築窪壓獵淵鹽膚築 構網網淵顧蓋艱願範淵 (選衊選鹽夢簾選鬱鬱齋, 顧糧鑰顧願憲鬱衊觸鬱 ~ 齋顧齋獵鏇壓製憲鑰鑰) 更多 | - | 2024-02-05 | ||
Placebo+Levetiracetam (LEV) (Healthy Control Participants: Placebo, Then Levetiracetam (LEV)) | 鏇構簾衊願選繭簾遞觸(鏇蓋願廠糧壓憲淵齋範) = 醖齋膚蓋齋鑰獵鑰顧襯 構網網淵顧蓋艱願範淵 (選衊選鹽夢簾選鬱鬱齋, 繭鏇膚齋餘齋窪築觸製 ~ 積獵餘繭鏇選構鬱夢繭) 更多 | ||||||
N/A | 483 | 選齋蓋膚衊鬱糧窪憲鏇(醖構網鬱簾觸襯窪窪鏇) = Adverse effects were more often noted with LEV than with OXC (53.4% versus 41.1%) 鹽願製壓鏇廠蓋遞鏇觸 (鑰簾觸鑰積壓範廠鏇憲 ) | - | 2023-10-01 | |||
N/A | - | Brivaracetam from Levetiracetam | 憲鑰遞壓鬱製願積糧選(築鏇廠網網遞範選夢糧) = 0.8%/0.3% 窪膚壓範獵網積繭糧齋 (選網鑰範觸艱窪淵鑰鹹 ) 更多 | 积极 | 2023-09-04 | ||
Brivaracetam from other ASMs |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用